markus-spiske-hvsr_cvecvi-unsplash

Owkin and Merck enter collaboration agreement for AI-powered cancer diagnostics

Betsy Goodfellow | December 20, 2023 | News story | Research and Development |ย ย AI diagnostics, Cancer, MSD, Merck, Oncology, Owkinย 

Owkin and Merck, known as MSD outside of the US and Canada, have announced that they have entered into a collaboration agreement for the development and commercialisation of AI-powered digital pathology diagnostics for the European Union (EU) market.

The collaboration has a focus on developing a pre-screening procedure to improve testing rates for MSI-H in endometrial, gastric, small intestinal and biliary cancers, with the collaboration initially focused in the EU.

Owkin also intends to expand the development of these AI diagnostics into four new cancer types.

Advertisement

Meriem Sefta, chief diagnostics officer at Owkin, commented: โ€œThis strategic alliance with MSD is focused on improving the way patients are diagnosed and receive treatment, advancing our shared mission of supporting healthcare providers in their adoption of innovative digital diagnostics. It is clear that there is a need for AI diagnostics that can both ease bottlenecks and resource pressures while also ramping up biomarker testing to match patients with optimal treatments.โ€

Scott K Pruitt, associate vice president and head of Translational Oncology at MSD Research Laboratories, added: โ€œThe application of AI technologies holds tremendous potential in the screening of patients and the diagnosis of disease. We look forward to working with the Owkin team toward harnessing this opportunity to identify more patients with MSI-H cancers who may benefit from ICI therapy.โ€

Betsy Goodfellow

Related Content

nerve-cell-2213009_960_720

Central nervous system cancer metastases โ€“ the evolution of diagnostics and treatment

The current forms of immunotherapy, how T cell therapy works and what the future holds

BioMed X and Servier launch Europeโ€™s first XSeed Labs to advance AI-powered antibody design

BioMed X and Servier have announced the launch of Europeโ€™s first XSeed Labs research project, …

T-cell therapy โ€“ the evolution of cancer treatments

The current forms of immunotherapy, how T cell therapy works and what the future holds

The Gateway to Local Adoption Series

Latest content